Farms.com Home   News

NCGA Praises USDA for Taking Science-Based Stance on New Product Regulation

The National Corn Growers Association praised the announcement made last week by Secretary of Agriculture Sonny Perdue publicly stating that the U.S. Department of Agriculture “does not regulate or have plans to regulate plants that could otherwise have been developed through traditional breeding techniques as long as they are not plant pests or developed using plant pests.”
 
This announcement shows the dedication of the USDA to develop common-sense regulatory solutions which are strongly based in science. By recognizing the way in which new technologies work and creating processes that ensure safety, our government allows farmers access to the tools necessary to combat ever-changing field conditions and improve the health of their crop.
 
We are pleased to see our government strive to unencumber the economy from the chains of costly, unnecessary over-regulation. By taking this stance, the USDA has put our government in a leadership position on how this technology can be accepted across agencies and countries.
 

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.